Robert Talac: Platelet Concentration Gap – PRP vs Advanced PRF
Robert Talac, Medical Director at Renaxis Regenerative Orthopedic Center, shared a post on LinkedIn:
“PRP Has More Platelets. Except When It Doesn’t.
I’ve made two arguments in my last 2 posts:
1. Standard PRP contains foreign substances. PRF – in plain glass tubes – doesn’t.
2. PRP’s growth-factor burst is the wrong delivery profile for durable regeneration.
Here’s the counterargument I hear most often:
‘Fine. But PRP still delivers higher platelet concentration.’
Let’s look at the numbers.
Standard PRP across most commercial systems:
3-8x whole blood concentration.
Buffy-coat PRP systems tend to be on the higher end.
Some reach slightly above 8x.
Now PRF:
- A-PRF (solid fibrin): 17.9x whole blood
- CGF (solid PRF derivative): 15.5x
- C-PRF (liquid): 12-17x – with some preparations exceeding 20x
Miron et al. quantified C-PRF from the buffy-coat fraction and reported increases of 1,200-1,700% over whole blood.
Concentrations routinely above 2,000-3,000 x 10⁹/L.
At those levels, we’re no longer talking about a marginal difference from PRP.
We’re looking at a fundamentally different concentration range.
To be precise: these are advanced PRF formulations – A-PRF, CGF, C-PRF – not standard low-speed PRF. Technique and protocol matter. But that’s exactly the point.
The field has moved.
Advanced PRF preparations have closed – and in most cases, reversed – the platelet concentration gap that once gave PRP its primary quantitative advantage.
The argument for PRP on concentration grounds was never rock-solid.
Against modern PRF protocols, it doesn’t hold at all.
Three arguments for PRP orthodoxy. Three answers from the evidence.”
Stay updated with Hemostasis Today.
-
Mar 27, 2026, 16:23Nathan Wong: Lp(a) Testing as a Class I Recommendation in 2026 Guidelines
-
Mar 27, 2026, 16:21Jeff Sternlicht: Inflammation is The ‘Storm’ Before Atherosclerosis
-
Mar 27, 2026, 16:19Laura Baglow-Micic: Register for the Transfusion Research Network for The SWiFT Trial Results Webinar
-
Mar 27, 2026, 16:18Chris Hannay: Rising Demand for Immunoglobulin Driving Plasma Industry Growth in Canada
-
Mar 27, 2026, 15:33Caitlin Raymond: A Manifesto on Three Foundational Values for a Real Culture of Wellness
-
Mar 27, 2026, 15:30Shankar Biswas: Impact of Coronary Collaterals on Mortality in STEMI
-
Mar 27, 2026, 15:21Joseph Ebubechukwu: The Hidden Impact of Elevated PCV on Patient Wellbeing
-
Mar 27, 2026, 14:53Tooba Rehman: Extending Impella 5.5 Support Beyond 14 Days in Cardiogenic Shock
-
Mar 26, 2026, 17:33Melissa Bouchard: Navigating Prosthetic Valves and Anticoagulation in Pregnancy at ACHD Hive Talks